SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Xencor (XNCR) -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (26)8/19/2014 7:40:57 PM
From: tuck  Respond to of 136
 
I guess I'm more sanguine about the RA/autoimmune program; there seems to be less competition by XmAb 5871's mechanism. FWIW, for those not aware, XmAb 5871 is AMG729. P2 supposed to read out late this year, I hear.

Cheers, Tuck



To: tuck who wrote (26)8/26/2014 2:11:57 AM
From: tuck  Read Replies (1) | Respond to of 136
 
I guess we can add KITE to my list of competitive concerns for 5574.

KITE CD19 program yields good data

Cheers, Tuck


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News